Gyre Therapeutics, Inc. (GYRE)
6.71
+0.02
(+0.30%)
USD |
NASDAQ |
Sep 16, 13:26
Gyre Therapeutics Price to Book Value : 6.592 for Sept. 16, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 6.573 |
| September 14, 2026 | 6.573 |
| September 11, 2026 | 6.612 |
| September 10, 2026 | 6.622 |
| September 09, 2026 | 6.828 |
| September 08, 2026 | 7.044 |
| September 04, 2026 | 6.740 |
| September 03, 2026 | 6.327 |
| September 02, 2026 | 6.248 |
| September 01, 2026 | 6.356 |
| August 31, 2026 | 6.455 |
| August 28, 2026 | 6.474 |
| August 27, 2026 | 6.563 |
| August 26, 2026 | 6.533 |
| August 25, 2026 | 6.563 |
| August 24, 2026 | 6.327 |
| August 21, 2026 | 6.789 |
| August 20, 2026 | 6.897 |
| August 19, 2026 | 7.024 |
| August 18, 2026 | 6.858 |
| August 17, 2026 | 6.690 |
| August 14, 2026 | 6.563 |
| August 13, 2026 | 6.425 |
| August 12, 2026 | 6.543 |
| August 11, 2026 | 6.524 |
| Date | Value |
|---|---|
| August 10, 2026 | 6.602 |
| August 07, 2026 | 6.553 |
| August 06, 2026 | 6.288 |
| August 05, 2026 | 6.121 |
| August 04, 2026 | 6.042 |
| August 03, 2026 | 6.003 |
| July 31, 2026 | 5.649 |
| July 30, 2026 | 5.708 |
| July 29, 2026 | 5.541 |
| July 28, 2026 | 5.885 |
| July 27, 2026 | 6.022 |
| July 24, 2026 | 5.836 |
| July 23, 2026 | 5.904 |
| July 22, 2026 | 5.836 |
| July 21, 2026 | 5.954 |
| July 20, 2026 | 5.777 |
| July 17, 2026 | 5.944 |
| July 16, 2026 | 6.307 |
| July 15, 2026 | 6.445 |
| July 14, 2026 | 6.229 |
| July 13, 2026 | 6.229 |
| July 10, 2026 | 6.406 |
| July 09, 2026 | 6.740 |
| July 08, 2026 | 6.740 |
| July 07, 2026 | 6.887 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Cytokinetics, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 3.606 |
| Alnylam Pharmaceuticals, Inc. | 23.84 |
| Anika Therapeutics, Inc. | 2.057 |
| Savara, Inc. | 7.478 |
Price to Book Value Related Metrics
| PS Ratio | 5.439 |
| PEG Ratio | -0.0210 |
| Price | 6.71 |
| Earnings Yield | -2.92% |
| Market Cap | 711.49M |
| PEGY Ratio | -0.0210 |